Загрузка...
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
Multiple myeloma (MM) has a worldwide incidence of 1–5/100,000/year. Outcomes have improved significantly in recent years following incorporation of immunomodulatory drugs and proteasome inhibitors into standard-of-care regimes. MM is profoundly immunosuppressive, enabling immune evasion, proliferat...
Сохранить в:
| Опубликовано в: : | Ther Adv Hematol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6582283/ https://ncbi.nlm.nih.gov/pubmed/31244984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719854171 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|